8-K: Intellia Therapeutics Announces Positive Phase 1 Data for CRISPR Gene Editing Therapy in ATTR Amyloidosis

Intellia Therapeutics reports positive Phase 1 clinical trial results for nexiguran ziclumeran (nex-z), a CRISPR-based gene editing therapy, showing potential for disease stabilization and improvement in patients with transthyretin (ATTR) amyloidosis.

Summary

• Intellia Therapeutics announced positive results from its Phase 1 trial of nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis.
• The study included patients with both ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
• In the ATTR-CM arm, a single dose of nex-z led to a 90% mean reduction in serum TTR at 12 months, with a mean residual concentration of 17 g/mL.
• 11 patients with 24 months of follow-up showed sustained TTR reduction with no waning effect.
• 81%, 94%, and 77% of ATTR-CM patients showed stability or improvement in NT-proBNP, hs-Troponin T, and 6-minute walk test, respectively, at 12 months.
• 66% of ATTR-CM patients showed stability or improvement across all three markers.
• 92% of ATTR-CM patients were stable or improved in their NYHA functional classification.
• The hospitalization rate for cardiovascular events in the ATTR-CM group was 0.16 per patient per year.
• In the ATTRv-PN arm, patients receiving 0.3 mg/kg or higher of nex-z had a 91% mean serum TTR reduction at 12 months, with a mean residual concentration of 20 g/mL.
• 16 patients with 24 months of follow-up in the ATTRv-PN arm showed sustained TTR reduction.
• Favorable trends were observed in ATTRv-PN patients based on the Neuropathy Impairment Score (NIS), modified Neuropathy Impairment Score (mNIS+7), and modified BMI (mBMI).
• Nex-z was generally well-tolerated in both arms, with mild to moderate infusion-related reactions being the most common adverse event.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical trial results with strong efficacy and a good safety profile, suggesting a significant advancement in the treatment of ATTR amyloidosis. The results are likely to be viewed very favorably by investors.

Positives

• Nex-z demonstrated rapid, deep, and sustained reduction in serum TTR levels in both ATTR-CM and ATTRv-PN patients.
• The treatment showed evidence of disease stabilization or improvement across multiple markers of disease progression in both patient groups.
• The safety profile of nex-z was favorable, with most adverse events being mild to moderate infusion-related reactions.
• The results support the hypothesis that greater TTR reduction may lead to greater clinical benefit in ATTR amyloidosis.
• The data suggests a potential disease-modifying effect of nex-z.

Negatives

• The most common adverse events were infusion-related reactions, although they were predominantly mild to moderate and did not result in discontinuations.
• Some patients showed no improvement in certain disease markers, indicating that the treatment is not universally effective.

Risks

• The success of the Phase 3 MAGNITUDE and MAGNITUDE-2 studies is not guaranteed.
• Regulatory approvals for nex-z are not certain.
• The results of the Phase 1 trial may not be predictive of future results in larger studies.
• The collaboration with Regeneron Pharmaceuticals, Inc. may not continue or be successful.
• There are risks related to intellectual property protection and third-party intellectual property.

Future Outlook

Intellia is moving forward with Phase 3 studies (MAGNITUDE and MAGNITUDE-2) based on the positive Phase 1 results, with the belief that greater TTR reduction may lead to greater clinical benefit. The company is also planning to present further data in the future.

Management Comments

• Intellia President and Chief Executive Officer John Leonard, M.D., stated that the data offers compelling evidence that deep and persistently low levels of TTR reduction achieved with nex-z may favorably impact disease progression for people living with ATTR amyloidosis.
• He also noted the stability or improvement observed after a single dose of nex-z in multiple markers of cardiac disease progression is remarkable, especially considering the high proportion of patients with cardiomyopathy who had advanced heart failure.
• Management believes the results from the ongoing Phase 1 study increase their belief in the likelihood of success of their active Phase 3 studies.

Industry Context

This announcement is significant in the gene editing space, as it provides further evidence of the potential of CRISPR-based therapies for treating rare diseases like ATTR amyloidosis. The results position Intellia as a leader in the development of in vivo gene editing therapies, potentially challenging existing treatments and offering a one-time treatment option.

Comparison to Industry Standards

• Current treatments for ATTR amyloidosis primarily focus on slowing the progression of the disease, whereas nex-z aims to address the root cause by reducing TTR production.
• The 90-91% TTR reduction achieved by nex-z is notably higher than what is typically seen with other therapies, such as TTR stabilizers or RNA interference drugs.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals have developed RNAi and antisense oligonucleotide therapies for ATTR amyloidosis, but these require ongoing administration, unlike the one-time treatment approach of nex-z.
• The observed stabilization and improvement in cardiac and neurological markers in the Phase 1 trial are promising and could potentially position nex-z as a superior treatment option if these results are confirmed in Phase 3 trials.
• The hospitalization rate of 0.16 per patient per year for cardiovascular events in the ATTR-CM group is a positive indicator, suggesting a potential reduction in disease burden compared to historical data.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data.
• Patients with ATTR amyloidosis may have a new, potentially more effective treatment option.
• Employees of Intellia may be motivated by the positive results and the potential impact of their work.
• The collaboration with Regeneron Pharmaceuticals, Inc. may be strengthened by the positive data.

Next Steps

• Intellia will continue with the Phase 3 MAGNITUDE study for ATTR-CM.
• Intellia will initiate and complete the Phase 3 MAGNITUDE-2 study for ATTRv-PN.
• The company will present further data from the Phase 1 trial in the future.
• Intellia will host an investor webcast to discuss the Phase 1 data.

Key Dates

Keywords

CRISPR, gene editing, ATTR amyloidosis, nexiguran ziclumeran, NTLA-2001, transthyretin, TTR reduction, cardiac disease, neuropathy, clinical trial, Phase 1, Regeneron